Octozi - About the company
Octozi is a seed company based in Russia, founded in 2023 by Amit Patel. It operates as an Accelerating life sciences with generative AI. Octozi has raised $3M in funding from Surface Ventures. The company has 1988 active competitors, including 102 funded and 207 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.
Company Details
Accelerating life sciences with generative AI. It helps sponsors integrate disparate datasets, automate clinical development processes, and accelerate data cleaning and review. This automation, powered by Generative Artificial Intelligence (AI) and advanced machine learning analytics, significantly reduces time to market. The platform improves patient safety through AI-driven early safety signal detection, enabling faster corrective actions. It offers real-time detection of clinical data discrepancies, going beyond basic edit checks. The AI visualizes and monitors clinical data for safety and efficacy, identifying nuanced and critical risks. A core design principle is security, ensuring compliance and data privacy. Robust accreditation and certifications meet industry gold standards for information security, patient data privacy, and compliance. The platform is designed to handle the needs of various life science organizations across all phases of clinical trials and therapeutic areas. It uses custom-developed large language models (LLMs) for optimal performance. All data remains confidential and is never used to train models.
Key Metrics
Founded Year
2023
Location
Stage
Seed
Total Funding
$3M in 2 rounds
Latest Funding Round
Investors
Ranked
136th among 1988 active competitors
Employee Count
6 as on Aug 31, 2026
Sign up to download Octozi's company profile
Octozi's funding and investors
Octozi has raised a total funding of $3M over 2 rounds. Its latest funding round was a Seed round on Jul 07, 2026 for $*****. 2 investors participated in its latest round. Octozi has 3 institutional investors.
Here is the list of recent funding rounds of Octozi:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 07, 2026 | 2603748 | Seed | 6926149 | 2323584 | 7453450 | 6489927 |
View details of Octozi's funding rounds and investors
Octozi's founders and board of directors
Founder? Claim ProfileThe founders of Octozi is Amit Patel.
Here are the details of Octozi's key team members:
- Amit Patel: Co-founder and CEO of Octozi.
View details of Octozi's Founder profiles and Board Members
Octozi's employee count trend
Octozi has 6 employees as of Aug 26. Here is Octozi's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Octozi's Competitors and alternates
Top competitors of Octozi include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Octozi, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 83/100 | |
2nd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 79/100 | |
4th | AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th | Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 75/100 | |
7th | Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 71/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
9th | Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
10th | Genentech 1976, San Francisco (United States), Acquired | R&D company focused on manufacturing drugs for multiple therapeutic areas | $72.5M | 68/100 | |
136th | Accelerating life sciences with generative AI | $3M | 40/100 |
Looking for more details on Octozi's competitors? Click here to see the top ones
Octozi's Investments and acquisitions
Octozi has made no investments or acquisitions yet.
Reports related to Octozi
Here is the latest report on Octozi's sector:
News related to Octozi
Media has covered Octozi for a total of 2 events in the last 1 year.
•
Octozi Raises $3M in Seed Funding to Bring Agentic AI to Clinical DevelopmentGlobeNewswire•Jul 07, 2026•Debiopharm, Remarkable Ventures, Octozi, Surface Ventures
•
Exclusive: How a Swiss pharma got to Octozi’s cap table before any US VC didTech Funding News•Jul 07, 2026•Octozi
Are you a Founder ?
FAQs about Octozi
Explore our recently published companies
- Christoph Hein - Lemwerder based, Unfunded company
- Sandra Godwin - Unfunded company
- KCG - Unfunded company
- Omnipresence Exim - Hyderabad based, 2019 founded, Unfunded company
- ValaCare - Toronto based, 2026 founded, Unfunded company
- AI Fairness 360 - Unfunded company